ArticleTurkish journal of pharmaceutical sciences2025
Dissolution Enhancement of Lycopene Compacts by Liquisolid Technique.
Article in Turkish journal of pharmaceutical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cubosomal nanoparticles of lycopene as a novel platform for enhancement in antioxidant and anticancer properties with a molecular docking study.Scientific reports · 2026Article
- Amorphous Lycopene-PVP K30 Dispersions Prepared by Ball Milling: Improved Solubility and Antioxidant Activity.Polymers · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Lycopene is a powerful antioxidant with diverse health benefits. However, it belongs to the Biopharmaceutics Classification System II; thus, it depicts poor water solubility and dissolution. Its lipophilic nature hinders the bioavailability of this drug. To overcome these limitations, namely, poor solubility and bioavailability, several approaches have been tried so far, such as co-solvency, size reduction or micronization, complexation, adsorption on high surface area carriers, etc. The present research aimed to apply the liquisolid technique to prepare lycopene liquisolid compacts with an improved dissolution profile. The impact of parameters such as carrier and drug concentration percentage on drug dissolution was evaluated in liquisolid compacts. Materials and Methods: Lycopene was extracted by Soxhlet extractionand then characterized by ultraviolet spectroscopy, infrared spectroscopy, thin-layer chromatography, and melting point. Liquisolid compacts of lycopene were formulated by using excipients such as non-volatile solvent (glycerine), carrier (Avicel PH 101, Fujicalin, Neusilin US2), disintegrant (Croscarmellose sodium), and diluent (lactose). The different formulation batches of liquisolid compacts were formulated and evaluated based on different pre-compression and post-compression parameters. Results: Powder X-ray Diffraction (PXRD) and Fourier transform infrared spectroscopy were utilized to analyze drug-excipient interaction; these studies showed no evidence of any physical or chemical interaction between the drug(s) and the excipients. The PXRD of lycopene showed sharp and intense peaks at diffraction angles (2θ) such as 12.563, 19.176, 19.636, 20.062, 21.283, 26.629, 29.479, 30.235, and 39.997, which indicates a crystallinestructure. The PXRD of the physical mixture of lycopene and excipients showed similar sharp peaks (12.582, 19.202, 19.634, 20.045, 21.304, 26.565, 29.474, 30.250, and 40.065), indicating thatthere is no drug-excipient interaction occurring. Lycopene was extracted and characterized. IR spectroscopy and PXRD showed no drug-excipient interaction. The lycopene liquisolid compacts passed both pre-compression and post-compression evaluations within acceptable limits. Conclusion: The formulation batch F-7, formulated with Neusilin US2 as a carrier and 40% drug concentrationshowed 98%
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.